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HTLV-1 orf-I is important for immune evasion, viral
replication and persistence. Here, we analyzed proviral
sequences isolated from ex vivo PBMC samples of 163
HTLV-1-infected patients (85 carriers, 78 HAM/TSP).
Of the 5000 sequences analyzed, orf-I expression was
consistently maintained. While the highest percentage of
isolates express both p12 and p8 (69%), the mutants
that express mainly p8 (7%) or mainly p12 (24%) were
highly correlated with decreased proviral loads. To
determine the individual role of p12 and p8 in viral persis-
tence, we constructed infectious molecular clones expres-
sing either p12(G29S) or p8(N26) and established
producer cell lines used to infect macaques. Three of four
macaques infected with WT-HTLV-1 tested positive by
PCR and were seropositive. Only one of the macaques
infected with N26-HTLV-1 tested positive by PCR and
two macaques were seropositive. None of the 8 animals
infected with G29S-HTLV-1 tested PCR positive or sero-
converted. These results suggest that expression of both
p12 and p8 are critical for viral persistence. Since orf-I
plays a role in T-cell activation and recognition, we com-
pared the CTL responses elicited by CD4+ T-cell infected
with the different HTLV-1 clones. Although the superna-
tant p19 levels and proviral loads for all four infected lines
were similar, a significant difference in Tax-specific CTL
killing was observed. Cells infected with orf-I-knockout
virus, p12-G29S or p8-N26 were killed whereas cells
infected with WT virus were not killed by Tax-specific
CTLs. These results indicate that efficient viral persistence
and spread requires expression of both p12 and p8.
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